natgillin/translations-raw huggingface dataset:
A mixture of methyl lithium (1.4 M solution in diethyl ether, 475 ml) and dry THF (5000 ml) was cooled to -40 ° C. A solution of the product obtained in the previous step (54 g) in dry THF (1000 ml) was added and the reaction mixture was stirred at room temperature overnight. 
- Smjesu metillitija (1,4 M otopina u dietil-eteru, 475 ml) i suhom THF (5000 ml) ohladi se do -40 *C. Doda se otopina produkta dobivenog u prethodnom koraku (54 g) u suhom THF (1000 ml), a reakcijsku smjesu miješa preko noći na sobnoj temperaturi.
The aqueous phase was extracted with ethyl acetate, the organics were combined, dried over MgSO4, filtered and evaporated. 
Vodena faza se ekstrahira s etil acetatom, organski dijelovi se spoje, osuše preko MgSO,, filtrira se i upari.
A method for manufacturing a compound of formula I (Compound I) or a salt thereof, which method comprises conversion of a compound of formula Va (Compound Va) in cis-configuration to the compound of formula I, wherein I and Va are as follows: 
Postupak proizvodnje spoja formule I (Spoj I) ili njegove soli, taj postupak obuhvaća pretvorbu spoja formule Va (Spoj Va) u cis-konfiguraciji u spoj formule I, pri čemu su I i Va: [image]
The multi-armed polymer prodrug of claim 1, wherein D is a small molecule having a molecular weight of less than about 800. 
Višestruko razgranati polimerni prolijek iz patentnog zahtjeva 1, pri čemu je ukupna prosječna molekulska masa prolijeka u rasponu od 20 000 do 80 000 Daltona.
untreated control nails onychoschizia 
Netretirani kontrolni nokti Listanje noktiju
means a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-C10)-alkyl group, a (C1-C10)alkoxy group, a (C1-C10)-alkylthio group, or a (C1-C5)-perfluoroalkyl group, 
predstavlja atom vodika, hidroksilnu skupinu, atom halogena, cijano skupinu, proizvoljno supstituiranu (C1-C10)-alkilnu skupinu, (C1-C10)alkoksi skupinu, (C1-C10)-alkiltio skupinu ili (C1-C5)-perfluoroalkilnu skupinu,
The method according to any of the previous claims, comprising a step of obtaining the sound propagation parameters, consisting of speed and attenuation, in the various pipe sections of the pipeline (12) by processing the composite signals, evaluating the correlation of the vibroacoustic measurements between adjacent measurement stations (14), wherein the signal to be processed consists of both the acoustic noise generated by the pig device (10) moving along the pipeline (12) and by pressure variations in the fluid. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uključuje korak dobivanja parametara širenja zvuka, koje čine brzina i prigušenje, u različitim cijevnim odjeljcima cjevovoda (12) obradom složenih signala, procjenjivanja korelacije vibroakustičnih mjerenja između susjednih mjernih postaja (14), gdje se xn) = HR P20171911 T1 signal koji treba obraditi sastoji i od akustične buke koju generira prasica (10) dok se kreće po cjevovodu (12) i od varijacija tlaka u fluidu.
An annular upper edge 9 or 51, see also Figure 5, of shell 14 is immediately adjacent the curl 34 of the cup body 12 and may abut same from below. The shell 14 extends downwardly from there to a narrow, annular surface where it engages at least partially the annular outer surface 38 of the upper wall section 37 at and slightly above the lower edge 41 of the shoulder 32. 
Gornji prstenasti rub 9 ili 51, vidi također sliku 5, ljuske 14 je neposredno uz zavijutak 34 tijela čaše 22 1 može doći do istoga s donje strane, Ljuska 14 se pruža odavde prema dolje prema uskoj prstenastoj površini gdje ona zahvaća barem djelomično gornju sekciju stijenke 37 i vanjsku prstenastu površinu 38 i to neznatno iznad donjeg ruba 41 izbočine 32.
A modified PH20 polypeptide, comprising one or more amino acid replacements in an unmodified PH20 polypeptide, wherein: 
Modificirani PH20 polipeptid, koji sadrži jednu ili više aminokiselinskih zamjena u nemodificiranom PH20 polipeptidu, naznačen time što:
The process of claim 1, wherein the step of reacting a compound of formula 6b with a compound of formula 11 occurs in the presence of a solvent and an organic base. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time, da se korak reakcije spoja formule 6b sa spojem formule 11 odvija u prisutnosti otapala i organske baze.
The device according to claim 1, wherein the raised engagement portion comprises an engagement surface, the engagement surface is elastic and seals against the flexible wall of the cartridge. 
Uređaj u skladu s patentnim zahtjevom 6, naznačen time što radna površina je i sama elastična, što omogućuje brtvljenje na stijenci kapsule.
In particular the compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes (herein after referred to as the “Disorders of the Invention”). 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju stanja ili poremećaja povezanih s receptorima SIPI1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan i dijabetes neovisan o inzulinu.
A pharmaceutical composition comprising a compound as recited in any one of numbered embodiments 1 to 10 and a pharmaceutically acceptable carrier, diluent or excipient. 
9. - Farmaceutski sastav koji sadrži spoj, ili njegovu farmaceutski prihvatljivu sol ili solvat, prema bilo kojem od zahtjeva 1 do 8 i farmaceutski prihvatljiv nositelj, sredstvo za razrjeđivanje ili pomoćna tvar.
a heat engine coupled with the evaporator and condenser. The apparatus according to claim 6, comprising one or more at least substantially cylindrical and co-axial walls, separating the inside of the drum into a plurality of compartments. 
Uređaj (1) prema patentnom zahtjevu 10 ili 11, naznačen time da sadrži jednu ili više barem u osnovi cilindričnih i koaksijalnih stijenki, kojo razdjeljuju unutrašnjost bubnja (6) u mnoštvo pregradaka.
The prelyophilized formulation of claim 1, wherein the concentration of histidine is 20 mM and the concentration of trehalose is 100-200 mM, preferably 120 mM and the concentration of TAT-NR2B9c is 90 mg/ml. 
Preliofilizirana formulacija u skladu s patentnim zahtjevom 1, naznačena time što je koncentracija histidina 20 mM, koncentracija trehaloze je 100-200 mM, po mogućnosti 120 mM, a koncentracija TAT-NR2B9c je 90 mg/ml.
Advantageously, the calcium carbonate containing mineral present in the slurry has a weight median particle diameter of 0.01 um to 10 um, preferably from 0.2 um to 2 um, more preferably from 0.5 um to 1 um, as measured by Sedigraph. 
Postupak prema zahtjevu 1 ili 2, naznačen time da navedeni kalcijev karbonat koji sadrži mineral u suspenziji ima weight median particle diameter od 0.01 um do 10 um, poželjno od 0.2 um do 2 um, poželjnije od 0.5 um do 1 um.
The pyrazine derivative according to claim 6, wherein R1 is a hydrogen atom and R2 is a fluorine atom. 
Derivat pirazina u skladu sa zahtjevom 6, naznačen time, daje R1 atom vodika i R2 je atom fluora.
Nevertheless, resistant maltodextrin exhibits all or nearly all the technological properties of digestible maltodextrins. 
Pa ipak, rezistentni maltodekstrini posjeduju sva, ili gotovo sva tehnološka svojstva probavljivih maltodekstrina.
The pharmaceutical as claimed in claim 20, which comprises as a further active ingredient Benazepril, Captopril, Cilazapril, Enalapril, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Spirapril, Trandolapril or Zofenopril. 
Farmaceutski pripravak prema zahtjevu 20, naznačen time da kao dodatni aktivni sastojak sadrži Benazepril, Kaptopril, Cilazapril, Enalapril, Fosinopril, Imidapril, Lizinopril, Moeksipril, Perindopril, Kinapril, Ramipril, Spirapril, Trandolapril ili Zofenopril,
The results have been summarized in the figure 2. 
Rezultati su sumirani na slici 2.
Compositions for the treatment of vaginal infections with chronic inflammation 
PRIPRAVCI ZA TRETMAN KRONIČNIH UPALNIH VAGINALNIH INFEKCIJA
A mouse comprising at an endogenous mouse MHC II locus a first nucleotide sequence encoding a chimeric human/mouse MHC II a polypeptide and a second nucleotide sequence encoding a chimeric human/mouse MHC II B polypeptide, wherein a human portion of the chimeric MHC II a polypeptide comprises an extracellular domain derived from an a polypeptide of a human HLA-DR4 protein and the human portion of the chimeric MHC II B polypeptide comprises an extracellular domain derived from a B polypeptide of a human HLA-DR4 protein, wherein a mouse portion of the chimeric MHC II a polypeptide comprises transmembrane and cytoplasmic domains of a mouse H-2E a chain and a mouse portion of the chimeric MHC II B polypeptide comprises transmembrane and cytoplasmic domains of a mouse H-2E B chain, and wherein the mouse expresses a functional chimeric HLA-DR4/H-2E MHC II complex on a surface of a cell of the mouse. The mouse of clause 30, wherein the extracellular domain of the a polypeptide comprises human a1 and a2 domains. 
Glodavac prema bilo kojoj od prethodnih tvrdnji, pri čemu je glodavac miš, ima na endogenom lokusu mišjeg MHC II gena prvi nukleotidni slijed koji kodira kimerni MHC II a polipeptid čovjeka/glodavca i drugi nukleotidni slijed koji kodira kimerni MHC II (polipeptid čovjeka/glodavca, pri čemu se ljudski dio kimernog MHC II a. polipeptida sastoji od domena al 1 92 koje kodira ljudski genski lanac HLA-DR4 a, a ljudski dio kimernog MHC II fB polipeptida sastoji od domena (1 1 B2 koje kodira ljudski genski lanac HLA-DR4 g, pri čemu se mišji dio kimernog MHC II a. polipeptida sastoji od transmembranske i citoplazmatske domene mišjeg lanca H-2E a, a mišji dio kimernog MHC II f polipeptida sastoji od transmembranske 1 citoplazmatske domene mišjeg lanca H-2E [, i pri čemu miš ima funkcionalnu ekspresiju kimernog HLA-DR4/H-2E MHC II kompleksa na površini stanice miša.
Other embodiments of the inventions include methods of imaging one or more cells, organs or tissues comprising exposing cells to or administering to a subject an effective amount of a compound with an isotopic label suitable for imaging. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 12-14 za uporabu u slikovnoj metodi za jednu ili više stanica, organa ili tkiva.
The isolated population of cells of item 18, wherein cells in said population of cells express one or more of the proteins decorin, epiregulin, IGFBP-3, IGFBP-6, IL-2 R alpha, IL-17RC, IL-27, Latent TGF-beta binding protein I (LTBP), NCAM-1, Smad4, TFPI, TGF-beta R1/ALK5 or TIMP-2, 
Izolirana populacija stanica u skladu s patentnim zahtjevom 15, naznačena time što stanice u navedenoj populaciji stanica eksprimiraju jedan ili više proteina dekorin, epiregulin, IGFBP-3, IGFBP-6, IL-2 R alfa, IL-17RC, IL-27, latentni TGF-beta-vežući protein 1 (LTBP), NCAM-1, Smad4, TFPI, TGF-beta RI/ALKS ili TIMP-2, ili gdje stanice u navedenoj populaciji stanica eksprimiraju proteine dekorin, epiregulin, IGFBP-3, IGFBP-6, IL-2 R alfa, IL-17RC, IL-27, latentni TGF-beta-vežući protein 1 (LTBP), NCAM-I, Smad4, TFPI, TGF-beta RI/ALKS 1 TIMP-2.
The gastroretentive drug formulation of claim 8, where the formulation contains 375 mg of levodopa and 50 mg of carbidopa. 
Oblik lijeka koji se zadržava u želucu iz patentnog zahtjeva 5, pri čemu formulacija sadrži 375 mg levodopa i 50 mg karbidopa.
Recombinant integrase (0.26 ng) was incubated with the beads for 90 min at 37° C. Unbound enzyme was removed by washing the complex followed by addition of inhibitors and 0.1 fmol of P33 labeled target DNA. 
Rekombinantna integraza (0.26 ng) je inkubirana sa granulama 90 minuta na 37%C. Nevezani enzim je uklonjen ispiranjem kompleksa i zatim 10 dodavanjem inhibitora i 0.1 fmol P33 obilježene ciljne DNK.
The combination for use according to claim 1, wherein the solid tumor is non-small cell lung cancer, prostate, breast, colorectal, or ovarian cancer. 
Kombinacija za uporabu prema zahtjevu 1, gdje je rak dojke lokalno uznapredovali rak dojke.
Preferred amides are derived from ammonia, C1-3 alkyl primary amines, and di (C1-2 alkyl)amines. 
Preferirani amidi se dobivaju od amonijaka, C;_.; alkil primarnih amina i di(C;.2 alkiljamina.
supply conduit R rotational axes of the first and second toothed wheels 
(33) Država ili organizacija podnošenja prve prijave: NL
The method of claim 9 wherein the target epitope recognized by the variable regions of the 3rd and 4th CH3 domain-comprising polypeptide chain is different from the target epitope recognized by the variable region of the 1st or the 2nd CH3 domain-comprising polypeptide chain. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je ciljni epitop kojeg prepoznaju varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrži CH3 domenu različitu od ciljnog epitopa kojeg prepoznaje varijabilnu regiju prvog ili drugog polipeptidnog lanca koji sadrži CH3 domenu.
A method of preparing a hollow glucan particle or hollow cell wall particle encapsulating a terpene component in accordance with any one of claims 1 to 43, said method comprising the steps of; 
Metoda pripravljanja šuplje glukanske čestice ili čestica šupljih stjenki stanice za enkapsulaciju terpena temeljem bilo kojeg od prethodnih zahtjeva 1 do 43, koja metoda se sastoji od sljedećih koraka:
said detectable moiety is a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material, or 
odvojivog dijela odabranog između fluorescentne boje, enzima, supstrata, bioluminescentnog materijala, radioaktivnog materijala, i kemiluminescentnog materijala, i
determining from the current location for the subscribed mobile communication device (10, 20, 101) and the subscriber network identifiers currently active or stored in the subscribed mobile communication device (10, 20, 101) whether a new subscriber network identifier is to be provisioned on the subscribed mobile communication device (10, 20, 101); 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što dodatno uključuje davanje uputa pretplatničkom mobilnom komunikacijskom uređaju (10, 20, 101) da se odvoji od trenutne mreže ako se odredi da to nije mreža kojoj se daje prednost; davanje uputa pretplatničkom mobilnom komunikacijskom uređaju (10, 20, 101) da se ponovno spoji s mrežom kojoj se daje prednost.
Such equivalents are intended to be encompassed by the following claims. A binding molecule comprising at least one pharmacologically active agent and at least one binding site that binds to TMEM30A (SEQ ID NO: 9), wherein the at least one binding site that binds to TMEM30A is fused i) directly or ii) via an intervening amino acid sequence to the N-terminus of an Fc moiety. 
Vezivna molekula u skladu s patentnim zahtjevom 1, naznačena time što je najmanje jedno farmakološki aktivno sredstvo genetički fuzionirano s vezivnom molekulom, po mogućnosti gdje su najmanje dva mjesta vezanja genetički fuzionirana preko intervenirajućeg aminokiselinskog slijeda koji sadrži VH domenu molekule protutijela, ili gdje su najmanje dva mjesta vezanja genetički fuzionirana preko intervenirajućeg aminokiselinskog slijeda koji sadrži VL domenu molekule protutijela, po mogućnosti gdje intervenirajući aminokiselinski slijed dodatno sadrži peptidnu spojnicu.
A smoking article was built as shown in Figure 2 with a 10 mm pressed carbon fuel plug having the configuration shown in Figure 2A, but with no tobacco. 
Proizvod za pušenje napravljen je kao što je prikazano na sl. 2 sa čepom goriva od 10 mm od prešanog ugljika koji ima konfiguraciju prikazanu na sl. 2A, ali bez duhana.
an acoustic signalling device connected to a proximity sensor, said device is able to detect the approaching of a vehicle that is potentially dangerous for all the persons staying in the area of the accident: the operators responsible of returning to safe traffic conditions; the Police officers; the workers of mechanical emergency; and the same people of the vehicles that have been involved in the accident. 
- < napravu za akustično signaliziranje povezanu na senzor blizine, navedena naprava je sposobna da otkrije približavanje vozila koje je potencijalno opasno za sve osobe koje borave u području nezgode; operatore odgovorne za vraćanje u sigurne uvjete prometa; policijske službenike, radnike za mehaničku pomoć i one osobe iz vozila koja su bila uključena u nezgodu.
Then, the valve element 5 will return to its first position after release of the actuation member 17, and the metering chamber 4 will refill with liquid 4 due to the pressure in the container 3 acting on the liquid 4 . 
Zatim, element ventila 5 će se vratiti u svoj prvi položaj nakon rasterećenja elementa za pokretanje 17, i odmjerna komora 4 će se ponovno napuniti s tekućinom 4 zbog pritiska u spremniku 3 koji djeluje na tekućinu 4.
In the floating granules according to the invention, the alkaline agent is preferably selected from the group consisting of carbonates and bicarbonates and is particularly selected from the group consisting of sodium bicarbonate, sodium carbonate, sodium glycine carbonate, potassium bicarbonate, magnesium carbonate, calcium carbonate and admixtures thereof. 
Granula prema zahtjevu 1, naznačena time, da je spomenuto alkalijsko sredstvo odabrano iz skupine koju tvore karbonati i bikarbonati, te time, da je prvenstveno odabrano iz skupine koju tvori sljedeće: natrijev bikarbonat, natrijev karbonat, natrijev glicin-karbonat, kalijev bikarbonat, magnezijev karbonat i kalcijev karbonat.
operating, by the central control unit, the emission device to emit the countercurrent flow of pressurised gas or a countercurrent pulse of pressurised gas at the filter; 
upravljanje emisijskim sredstvima (14, 24, 15, 25) da se ispusti protustrujni protok stlačenog plina ili protustrujni puls stlačenog plina na tim filterima (13, 23);
The forming method according to any of the claims from 19 to 23, characterised in that during the sub-step of enriching the process air with pressurised nebulised water, the pressurised water taken from the water source (62), before being sent to the nozzle (60), is cooled in a cooling stage (64). 
Postupak oblikovanja prema bilo kojem od zahtjeva od 17 do 21, naznačen time da tijekom pod-koraka obogaćivanja zraka za postupak sa vodom u obliku magle pod tlakom, voda pod tlakom koja se uzima iz izvora vode (62), je prije slanja prema sapnici (60), ohlađena u fazi hlađenja (64).
A combination comprising a first active ingredient, which is at least one salt of a compound according to any of the claims 1 to 9, and a second active ingredient, which is at least one anti-cancer agent selected from the group consisting of chemotherapeutic anti-cancer agents and target-specific anti-cancer agents, for separate, sequential, simultaneous, concurrent or chronologically staggered use in therapy, such as e.g. in therapy of benign or malignant neoplasia, e.g. cancer. 
Kombinacija, naznačena time što sadrži prvi aktivni sastojak, koji je najmanje jedna sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9,1 drugi aktivni sastojak, koji je najmanje jedno sredstvo protiv raka, kojeg se bira iz skupine koju čine kemoterapijska sredstva protiv raka i ciljno specifična sredstva protiv raka, namijenjen odvojenoj, uzastopnoj, istodobnoj, paralelnoj ili kronološki razdijeljenoj upotrebi u terapiji, primjerice u terapiji dobroćudnih ili zloćudnih novotvorina, primjerice raka.
generating, on each network node of the number of network nodes (1, 2, 3, 4, 5, 6), a backup copy of the values of the data items (D1, D2, D3) and the log files stored on the network node, wherein performing, by the computer network (100), the consistency step (40) includes: 
- < Stvaranje, na svakom mrežnom čvoru broja mrežnih čvorova (1, 2, 3, 4, 5, 6), sigurnosne kopije vrijednosti podatkovnih stavki (D1, D2, D3) i dnevnika rada pohranjenih na mrežnom čvoru, pri čemu kada se izvršava, računalnom mrežom (100), stupanj konzistencije (40) uključuje:
A method according to claim 17 wherein once the temperature has been reduced to a sufficient extent, the pressure is also reduced so that the pressure and temperature are then further reduced to ambient conditions. 
Postupak prema zahtjevu 14 gdje se nakon što je temperatura dovoljno smanjena i tlak počinje smanjivati tako da se tlak i temperatura zatim dalje zajedno smanjuju do sobnih uvjeta.
One aspect of the invention relates to a set top box connectable to a receiver for receiving a digital video signal, wherein the set top box comprises the apparatus according to the invention. 
Digitalni video prijemnik koji se može povezati s prijemnikom za prijem digitalnog video signala, naznačen time što digitalni video prijemnik sadrži uređaj u skladu s patentnim zahtjevima 19 ili 20.
wherein the antibody does not cross-react with human GFRa1 or human GFRa2, and/or; 
(b) pri čemu antitijelo ne stupa u unakrsnu reakciju s ljudskim GFRa1 ili ljudskim GFRo2, i/ili;
A topical ophthalmic composition for use according to claim 1, characterized in that said treatment and/or prevention benefits from the binding of somatostatin or somatostatin analogue to the somatostatin receptors. 
Topikalna očna kompozicija u skladu sa zahtjevom 1, naznačena time što se tretman i/ili prevencija zasnivaju na vezivanju somatostatina ili analoga somatostatina za receptore somatostatina.
The compound of claim 3, wherein R is tetrahydro-2H-pyranyl. The compound selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine:
The compound of claim 13, wherein the compound is 2-[(2S)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a therapeutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 18, naznačen time, da je spoj 2-[(2S)-2-metilpirolidin-2-il]-1H-benzimidazol-4-karboksamid ili terapijski prihvatljiva njegova sol.
connecting an adjusting tool system to the secondary unit using the adjusting tool system to evaluate an accuracy of the voltage divider for a plurality of circuit configurations, each circuit configuration of said plurality of circuit configurations obtained by interconnecting a subset of said plurality of electronic components, and using a circuit configuration of said plurality of circuit configurations to influence the dividing ratio of the voltage divider; 
spajanje prilagodnog alatnog sustava (3) sa sekundarnom jedinicom(2), pri čemu prilagodni alatni sustav (3) ocjenjuje preciznost naponskog djelitelja za veći broj sklopnih konfiguracija, gdje sklopne konfiguracije međusobno spajaju jednu podskupinu elektroničkih komponenti (29), kako bi se generirao elektronički sklop koji ima utjecaj na omjer dijeljenja naponskog djelitelja;
The resulting solution can then be heated at 60°-130°C, preferably under reflux, until the reaction is essentially complete, typically in 24 hours or less. 
Dobivena otopina može se tada zagrijavati na 60%-130%C, poželjno pod refluksom, dok reakcija ne bude suštinski kompletna, tipično za 24 sata ili manje.
cooling the G-CSF composition provided in step (a) to a temperature of −15° C. or below to obtain a frozen G-CSF composition; 
(b) hlađenje G-CSF-sastava pribavljenog u koraku (a) do temperature od -I5C ili ispod toga za dobivanje zamrznute G-CSF-formulacije;
The formulation of anyone of claims 1 to 3 wherein the pH buffered saline solution of the formulations has a pH of 5.5 to 7.5 
Formulacija u skladu s patentnim zahtjevom 1, naznačena time što navedena fiziološka otopina s puferiranim pH ima pH od 5,5 do 7,5.